CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
CDT Equity has commenced human skin studies with QIMA Life Sciences evaluating its proprietary tapinarof combinations in vitiligo, formally kicking off the partnership announced September 18, 2026. The studies use human skin from healthy donors and patients to generate preclinical data in the most physiologically relevant setting available, which CDT says will underpin the licensing data package for out-licensing the combinations.
Key figures
- Drug Name
- tapinarof combinations
- Vitiligo prevalence
- 0.5%-2.0%
- Vitiligo market 2025 usd
- $2.6 billion
- Vitiligo market 2030 projected usd
- $6.6 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.